Evisort offers the next generation of AI-powered contract intelligence. Evisort’s AI platform for contract lifecycle management and analysis connects contract data, unlocks productivity, and delivers digital workflows that create great experiences across the enterprise.
Uncover combines decades of litigation experience with the newest technological enhancements to accelerate long overdue digitisation in the litigation workflow, freeing up substantial amounts of precious time for lawyers to drive efficiency and focus on strategy.
Corpora empowers founders and lawyers with the resources they need to get legal done: Smart Legal Drive helps the startup keep all of its legal documents in one repository – organized, accurate, and complete – and gives alerts in case certain important documents are missing. AI Assistant helps founders get plain language, actionable insights to their startup law questions.
Summize is pioneering true digital contracting with a CLM solution that puts the user experience first. It takes a deliberately different approach by embedding workflows directly into existing technologies that you (and your business) already know and use daily, including Outlook, Gmail, HubSpot, Teams, Slack and Word.
Ironclad is the smart way to make and manage digital business contracts. It's the only platform flexible enough to handle every type of contract workflow, whether a sales agreement, an HR agreement or a complex NDA.
Avokaado revolutionizes business operations with its new category product, the Operational Intelligence Platform (OIP). By leveraging the power of data-driven smart document format aDoc, artificial intelligence, and automation, Avokaado delivers unparalleled efficiency and intelligence in contract and document management across all business functions.
Plaintiffs Dow Jones & Company, Inc., NYP Holdings, Inc., and corporate parent News Corporation have renewed their intellectual property (IP) complaint against artificial intelligence (AI)-powered “answer engine” Perplexity AI in the District Court for the Southern District of New York.
The court in Thomson Reuters v. Ross Intelligence granted Ross’s request for interlocutory appeal on whether Westlaw’s headnotes are original and if Ross’s limited use (0.076%) qualifies as fair use. The court acknowledged differing legal opinions on these core issues, which could reshape the trial and have major implications for AI and copyright law.
In its most recent effort to keep pace with advancing technology, the US Food and Drug Administration (FDA) recently issued two draft guidances on the use of artificial intelligence (AI) in the context of drugs, biologics, and medical devices.
As artificial intelligence (AI) continues to develop at a rapid pace, even the most sophisticated general counsel (GC) and in-house legal teams will be hard pressed to keep up with the evolving legal landscape.
In the last year, state activism in healthcare consumer protection has surged, with new laws that heighten oversight of for-profit investors’ engagement with healthcare marketplaces and scrutinize pharmaceutical pricing practices. As part of this activism, several state legislatures have enacted laws regulating use of artificial intelligence (AI) in healthcare delivery.
The CNIL issued draft guidelines to align AI training datasets with GDPR. Key principles include purpose limitation (clear, specific goals), data minimization, storage limits, and the need for a legal basis (e.g. consent or legitimate interest). Vague goals like “AI development” aren’t valid. The CNIL recommends ethics committees and traceable governance. Reuse of data requires compatibility with original purpose. This aims to balance innovation with data protection.